Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

The aim of the study was to determine the maximum tolerated dose (MTD) and safety of the combination of bortezomib and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) as first-line therapy in advanced, aggressive T-cell lymphoma. Patients received increasing doses of bortezomib o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, J., Suh, C., Kang, H. J., Ryoo, B.-Y., Huh, J., Ko, Y. H., Eom, H.-S., Kim, K., Park, K., Kim, W. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2008
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2733119/
https://ncbi.nlm.nih.gov/pubmed/18689866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados